Category: Pα+ - Page 6 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos

Post published:October 4, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits

Post published:September 30, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more…

Post published:September 27, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Post published:September 20, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Real-World Data Reveals Variability in Access to, and Use of, Spravato

Real-World Data Reveals Variability in Access to, and Use of, Spravato

Post published:September 13, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Pα+ Psychedelic Bulletin #172: Lykos Scales Back IIT Program, CEO Steps Down; Psyence Scoops Up Clairvoyant for Peanuts; Mindstate’s Moxy Enters Phase I

Post published:September 9, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Exclusive: David Hough on Lykos’ Path to Resubmission

Exclusive: David Hough on Lykos’ Path to Resubmission

Post published:September 4, 2024
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown

Post published:August 30, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2)

Post published:August 28, 2024
Post category:Analysis News Pα+

Read more about the article What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 1)

Post published:August 22, 2024
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.